PortfoliosLab logoPortfoliosLab logo
EBF vs. BMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

EBF vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ennis, Inc. (EBF) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, EBF achieves a 16.85% return, which is significantly higher than BMY's 7.27% return. Over the past 10 years, EBF has outperformed BMY with an annualized return of 7.79%, while BMY has yielded a comparatively lower 0.75% annualized return.


EBF

1D
1.79%
1M
-0.15%
YTD
16.85%
6M
19.57%
1Y
17.02%
3Y*
9.24%
5Y*
6.81%
10Y*
7.79%

BMY

1D
3.44%
1M
-0.61%
YTD
7.27%
6M
11.38%
1Y
23.94%
3Y*
-0.48%
5Y*
1.28%
10Y*
0.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

EBF vs. BMY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
EBF
Ennis, Inc.
16.85%-9.96%12.59%3.64%19.38%14.78%-13.46%17.54%-2.77%24.65%
BMY
Bristol-Myers Squibb Company
7.27%0.11%15.81%-26.14%18.98%2.88%0.41%27.74%-12.90%7.71%

Correlation

The correlation between EBF and BMY is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.25

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (5Y)
Calculated over the trailing 5-year period

0.23

Correlation (10Y)
Calculated over the trailing 10-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Sep 25, 1987

0.18

Fundamentals

EPS

EBF:

$2.44

BMY:

$3.57

PE Ratio

EBF:

8.40

BMY:

15.87

PEG Ratio

EBF:

0.49

BMY:

0.91

PS Ratio

EBF:

1.21

BMY:

2.38

Total Revenue (TTM)

EBF:

$296.04M

BMY:

$48.48B

Gross Profit (TTM)

EBF:

$92.28M

BMY:

$33.33B

EBITDA (TTM)

EBF:

$75.72M

BMY:

$13.34B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

EBF vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EBF
EBF Risk / Return Rank: 6464
Overall Rank
EBF Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
EBF Sortino Ratio Rank: 5858
Sortino Ratio Rank
EBF Omega Ratio Rank: 5858
Omega Ratio Rank
EBF Calmar Ratio Rank: 6969
Calmar Ratio Rank
EBF Martin Ratio Rank: 6969
Martin Ratio Rank

BMY
BMY Risk / Return Rank: 6868
Overall Rank
BMY Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
BMY Sortino Ratio Rank: 6565
Sortino Ratio Rank
BMY Omega Ratio Rank: 6262
Omega Ratio Rank
BMY Calmar Ratio Rank: 7373
Calmar Ratio Rank
BMY Martin Ratio Rank: 7171
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EBF vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ennis, Inc. (EBF) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


EBFBMYDifference
Sharpe ratioReturn per unit of total volatility

-0.12

Sortino ratioReturn per unit of downside risk

-0.32

Omega ratioGain probability vs. loss probability

1.15

1.17

-0.02

Calmar ratioReturn relative to maximum drawdown

1.50

1.76

-0.26

Martin ratioReturn relative to average drawdown

3.54

3.87

-0.33

EBF vs. BMY - Sharpe Ratio Comparison

The current EBF Sharpe Ratio is 0.78, which is comparable to the BMY Sharpe Ratio of 0.90. The chart below compares the historical Sharpe Ratios of EBF and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


EBFBMYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.78

0.90

-0.12

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.32

0.05

+0.27

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.30

0.03

+0.27

Sharpe Ratio (All Time)

Calculated using the full available price history

0.19

0.35

-0.16

Drawdowns

EBF vs. BMY - Drawdown Comparison

The maximum EBF drawdown since its inception was -73.10%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for EBF and BMY.


Loading charts...

Drawdown Indicators


EBFBMYDifference

Max Drawdown

Largest peak-to-trough decline

-73.10%

-72.03%

-1.07%

Max Drawdown (1Y)

Largest decline over 1 year

-11.41%

-13.68%

+2.27%

Max Drawdown (3Y)

Largest decline over 3 years

-22.80%

-36.85%

+14.05%

Max Drawdown (5Y)

Largest decline over 5 years

-22.80%

-47.67%

+24.87%

Max Drawdown (10Y)

Largest decline over 10 years

-35.32%

-47.67%

+12.35%

Current Drawdown

Current decline from peak

-7.19%

-18.55%

+11.36%

Average Drawdown

Average peak-to-trough decline

-20.58%

-22.38%

+1.80%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.82%

6.20%

-1.38%

Volatility

EBF vs. BMY - Volatility Comparison

The current volatility for Ennis, Inc. (EBF) is 5.72%, while Bristol-Myers Squibb Company (BMY) has a volatility of 7.01%. This indicates that EBF experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


EBFBMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.72%

7.01%

-1.29%

Volatility (6M)

Calculated over the trailing 6-month period

16.45%

18.65%

-2.20%

Volatility (1Y)

Calculated over the trailing 1-year period

22.05%

26.81%

-4.76%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

21.41%

24.02%

-2.61%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

26.26%

25.26%

+1.00%

Dividends

EBF vs. BMY - Dividend Comparison

EBF's dividend yield for the trailing twelve months is around 4.87%, more than BMY's 4.42% yield.


PositionTTM20252024202320222021202020192018201720162015
BMY
Bristol-Myers Squibb Company
4.42%4.60%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%
EBF
Ennis, Inc.
4.87%5.55%16.60%4.56%4.51%4.86%5.04%4.16%4.94%3.61%11.67%3.64%

Financials

EBF vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between Ennis, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
11.49B
(EBF) Total Revenue
(BMY) Total Revenue
Values in USD except per share items

Frequently Asked Questions


EBF and BMY have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BMY has higher volatility (7.01%) compared to EBF (5.72%). In terms of maximum drawdown, EBF dropped -73.10% vs BMY's -72.03%.

BMY currently has the higher Sharpe Ratio (0.90 vs 0.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for EBF and BMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer